Infertility Clinical Trial
Official title:
A Prospective, Observational Study on the Use of Cetrotide (GnRH Antagonist) With GONAL-f in Assisted Reproductive Technologies (ART)
Verified date | January 2012 |
Source | Merck KGaA |
Contact | n/a |
Is FDA regulated | No |
Health authority | Singapore: Health Sciences Authority |
Study type | Observational |
This is a multicentric, prospective, observational study on the use of Cetrotide to control
the endogenous gonadotrophin levels in Gonal-f stimulated ART treatment cycles in the
Asia-Pacific region. The study plans to enrol approximately 1800-2000 subjects over a
9-month period at each participating centre.
This observational study is initiated to collect information on the use of Cetrotide (GnRH
antagonist) in ART cycles in routine practice across the Asia-Pacific region. The
information will allow a better understanding of the current ovarian stimulation regimens
that involve Cetrotide in the control of the endogenous gonadotrophin concentrations. The
collection of live birth data, though a challenging task, as a secondary endpoint will allow
the study to show valuable information on the final objective of ART. To minimize the
potential variability due to the different ovarian stimulation agents, the study is to
include cycles treated with Gonal-f (recombinant human FSH) since this agent is widely
available in the region.
Status | Completed |
Enrollment | 2175 |
Est. completion date | December 2010 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Subjects who are undergoing ovarian stimulation for IVF or ICSI therapy - Decision by treating physician to prescribe Gonal-f for controlled ovarian stimulation prior to study enrolment - Decision by treating physician to prescribe Cetrotide as the down-regulation agent prior to study enrolment Exclusion Criteria: - Subjects using GnRH agonist as the down-regulation agent - Contraindicated use of Cetrotide based on local label - Subjects who have participated in the study previously - Subjects with hypersensitivity to cetrorelix acetate, extrinsic peptide hormones or mannitol - Subjects with known hypersensitivity to GnRH or any other GnRH analogs - Subjects with known or suspected pregnancy, and lactation |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Singapore | Singapore General Hospital Pte Ltd, Outram Road | Singapore |
Lead Sponsor | Collaborator |
---|---|
Merck KGaA | Merck Pte. Ltd., Singapore |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of subjects achieving a clinical pregnancy. | A transvaginal ultrasound scan will be performed on all subjects who become pregnant provided that no miscarriage has occurred. | At post hCG days 35-42 | No |
Secondary | Proportion of subjects with cancelled cycles | 3 month | No | |
Secondary | Proportion of women with OHSS or risk of OHSS | 3 month | Yes | |
Secondary | Duration and dose of Cetrotide administered | 3 month | No | |
Secondary | Assessment of baseline characteristics | Assessment of subjects age, weight, height, FSH and LH level prior to Gonal-f administration, concomitant treatment, infertility history and infertility treatment | 3 month | No |
Secondary | Total dose of Gonal-f administered | 3 month | No | |
Secondary | Duration of ovarian stimulation | 3 month | No | |
Secondary | Number of oocytes retrieved | 3 month | No | |
Secondary | Number of subjects with Adverse Events | 3 month | Yes | |
Secondary | Pregnancy rate | 12 month | No | |
Secondary | Live birth rate | 12 month | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A |